Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients
NCT04604782Phase 2Recruiting
- Sponsor
- GE HealthCare
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of regadenoson in Myocardial ischemia (MI), coronary artery disease (CAD), sponsored by GE HealthCare. Started May 2021; status: recruiting.
02
Drugs
regadenoson
03
Conditions
Myocardial ischemia (MI)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04604782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604782.